Medivir First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Medivir (STO:MVIR) First Quarter 2025 Results

Key Financial Results

• Net loss: kr13.3m (loss narrowed by 49% from 1Q 2024).
• kr0.12 loss per share (improved from kr0.23 loss in 1Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medivir EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 60%. Earnings per share (EPS) exceeded analyst estimates by 45%.

Looking ahead, revenue is forecast to grow 52% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden.

Performance of the Swedish Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Medivir is showing 4 warning signs in our investment analysis and 3 of those are a bit concerning...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.